| pubmed-article:3092309 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3092309 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:3092309 | lifeskim:mentions | umls-concept:C0033809 | lld:lifeskim |
| pubmed-article:3092309 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:3092309 | lifeskim:mentions | umls-concept:C0004499 | lld:lifeskim |
| pubmed-article:3092309 | lifeskim:mentions | umls-concept:C0015309 | lld:lifeskim |
| pubmed-article:3092309 | lifeskim:mentions | umls-concept:C0020852 | lld:lifeskim |
| pubmed-article:3092309 | lifeskim:mentions | umls-concept:C0040341 | lld:lifeskim |
| pubmed-article:3092309 | lifeskim:mentions | umls-concept:C0243026 | lld:lifeskim |
| pubmed-article:3092309 | lifeskim:mentions | umls-concept:C1446680 | lld:lifeskim |
| pubmed-article:3092309 | lifeskim:mentions | umls-concept:C0314768 | lld:lifeskim |
| pubmed-article:3092309 | lifeskim:mentions | umls-concept:C0279023 | lld:lifeskim |
| pubmed-article:3092309 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:3092309 | pubmed:dateCreated | 1986-10-16 | lld:pubmed |
| pubmed-article:3092309 | pubmed:abstractText | Mice with cyclophosphamide-induced neutropenia were challenged with four immunotypes of Pseudomonas aeruginosa by contamination of a small dorsal surface wound. The infections were lethal; 100% of control animals (n = 80) treated only with albumin died. Administration of an immunoglobulin G intravenous preparation (IGIV) and/or therapy with tobramycin or azlocillin was begun 16 hr after challenge. Mortality among mice (n = 120) treated only with an antibiotic was 75.0%, while that among mice (n = 80) treated only with IGIV was 78.8%. Combination therapy with IGIV and an antibiotic (n = 120) resulted in mortality of 38.3%. The protection afforded by IGIV may have resulted in part from neutralization of exotoxin A, as mice treated with IGIV before challenge with exotoxin A were subject to lower mortality and had lower levels of serum aspartate and alanine aminotransferases than controls. | lld:pubmed |
| pubmed-article:3092309 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3092309 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3092309 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3092309 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3092309 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3092309 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3092309 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3092309 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3092309 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3092309 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3092309 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3092309 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3092309 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3092309 | pubmed:issn | 0162-0886 | lld:pubmed |
| pubmed-article:3092309 | pubmed:author | pubmed-author:CollinsM SMS | lld:pubmed |
| pubmed-article:3092309 | pubmed:author | pubmed-author:TsaiG SGS | lld:pubmed |
| pubmed-article:3092309 | pubmed:author | pubmed-author:DorseyJ HJH | lld:pubmed |
| pubmed-article:3092309 | pubmed:author | pubmed-author:RobyR ERE | lld:pubmed |
| pubmed-article:3092309 | pubmed:author | pubmed-author:HectorR FRF | lld:pubmed |
| pubmed-article:3092309 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3092309 | pubmed:volume | 8 Suppl 4 | lld:pubmed |
| pubmed-article:3092309 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3092309 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3092309 | pubmed:pagination | S420-5 | lld:pubmed |
| pubmed-article:3092309 | pubmed:dateRevised | 2004-4-8 | lld:pubmed |
| pubmed-article:3092309 | pubmed:meshHeading | pubmed-meshheading:3092309-... | lld:pubmed |
| pubmed-article:3092309 | pubmed:meshHeading | pubmed-meshheading:3092309-... | lld:pubmed |
| pubmed-article:3092309 | pubmed:meshHeading | pubmed-meshheading:3092309-... | lld:pubmed |
| pubmed-article:3092309 | pubmed:meshHeading | pubmed-meshheading:3092309-... | lld:pubmed |
| pubmed-article:3092309 | pubmed:meshHeading | pubmed-meshheading:3092309-... | lld:pubmed |
| pubmed-article:3092309 | pubmed:meshHeading | pubmed-meshheading:3092309-... | lld:pubmed |
| pubmed-article:3092309 | pubmed:meshHeading | pubmed-meshheading:3092309-... | lld:pubmed |
| pubmed-article:3092309 | pubmed:meshHeading | pubmed-meshheading:3092309-... | lld:pubmed |
| pubmed-article:3092309 | pubmed:meshHeading | pubmed-meshheading:3092309-... | lld:pubmed |
| pubmed-article:3092309 | pubmed:meshHeading | pubmed-meshheading:3092309-... | lld:pubmed |
| pubmed-article:3092309 | pubmed:meshHeading | pubmed-meshheading:3092309-... | lld:pubmed |
| pubmed-article:3092309 | pubmed:meshHeading | pubmed-meshheading:3092309-... | lld:pubmed |
| pubmed-article:3092309 | pubmed:meshHeading | pubmed-meshheading:3092309-... | lld:pubmed |
| pubmed-article:3092309 | pubmed:meshHeading | pubmed-meshheading:3092309-... | lld:pubmed |
| pubmed-article:3092309 | pubmed:meshHeading | pubmed-meshheading:3092309-... | lld:pubmed |
| pubmed-article:3092309 | pubmed:articleTitle | Immunoglobulin G: potentiation of tobramycin and azlocillin in the treatment of Pseudomonas aeruginosa sepsis in neutropenic mice and neutralization of exotoxin A in vivo. | lld:pubmed |
| pubmed-article:3092309 | pubmed:publicationType | Journal Article | lld:pubmed |
